Cencora (COR) concentration risks

The pharmaceutical distributor's customer concentration profile is well-disclosed and materially high, with the largest exposures stacked across a small number of relationships that together account for the majority of revenue. The top ten customers, including governmental agencies, represented approximately 66% of revenue in fiscal 2025 — a high-share dependency by disclosed size. This alone marks the top of the customer pyramid as the single most important variable in the revenue model. Within that group, two relationships are individually disclosed: Walgreens and Boots together accounted for approximately 25% of revenue in fiscal 2025, a moderate-share dependency in its own right, while Evernorth Health Services accounted for approximately 13% of revenue in fiscal 2025, a low-share exposure at the enterprise level but still a named, individually material relationship. The dependency character runs throughout: pharmaceutical distribution is a contractually intensive business where large customers have significant bargaining power over pricing and service-level terms, and a loss or meaningful reduction of a top-ten relationship would have a measurable impact on revenue. The concentration of revenue in a small number of large pharmacy chains, pharmacy benefit managers, and government customers is a structural feature of the wholesale distribution industry, not an idiosyncratic artifact of this company's choices, but it does mean that contract renewal cycles at Walgreens, Boots, Evernorth, and their peers are the most watched events in the revenue pipeline.

For the engine’s reasoning on COR’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.